glp-1 news 2025 november ISPOR 2025: Exploring reasons for discontinuation And so, my GLP-1 journey

So by combining their established behavioral support with powerful prescription medication, Noom aims to offer a highly holistic alternative to weight management

Keep it sustainable

In between, we can have an RN do a check to see how things are coming, make sure everythings okay

In March of this year, Wegovy was approved for overweight or obese patients with cardiovascular disease

PubMed Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis Used for liver-disease pages where semaglutide appears in exploratory NASH combination research

Neuroendocrine peptides such as relaxin-3 and phoenixin highlight the importance of indication alignment